Company hopes its FDA-cleared inhaler attachment will help reduce the $100 billion cost of treating asthma and chronic obstructive pulmonary diseaseĀ (COPD).
Company hopes its FDA-cleared inhaler attachment will help reduce the $100 billion cost of treating asthma and chronic obstructive pulmonary diseaseĀ (COPD).